Skip to main content

Corporate Educational Satellite Symposia

Subpage Hero

Corporate Educational Satellite Symposia

GeneDx

Tuesday, March 12, 2024: 4:00 PM – 5:30 PM
Delta Hotel Toronto - Kensington Ballroom

Equitable Access to Exomes and Genomes. Ordered by Whom?

This debate-style session will feature a moderator and a panel of providers that will discuss the following topic: Non-geneticists ordering genomic (exome or genome) sequencing within the scope of pediatric care. This balanced panel will be comprised of advocates and opponents of the topic and will include geneticists and non-geneticists.

Learning Objectives:

  • Summarize current practice guidelines and ACMG policy statements pertaining to genomic sequencing in pediatric settings.
  • Explain the current availability of the medical genetics workforce and the genomic testing access needs for pediatric patients
  • Compare and contrast viewpoints and opportunities around non-geneticists ordering genomic sequencing as part of routine care

Faculty: 
Matthew Deardorff, MD, PhD; Children’s Hospital Los Angeles
Wendy Chung, MD, PhD; Boston Children's Hospital 
Pankaj Agrawal, MD MMSc; University of Miami Miller School of Medicine and Holtz Children’s Hospital, Jackson Health System
Isum Ward, MD; University of South Dakota 
Nhung Tran, MD; Ascension Health 

Non-accredited

For more information and to register

Ultragenyx Pharmaceutical Inc.

Tuesday, March 12, 2024: 4:00 PM – 5:30 PM
Delta Hotel Toronto – Soco Ballroom

Implementing Gene Therapies into Your Genetics Clinic: Learnings from Other Specialties

To provide education to medical geneticists on how to implement gene therapies into their clinical practice utilizing the experience of other specialists. This seminar will focus on the implementation aspect as well as the administration, management, and monitoring characteristics of gene therapy.

Learning Objectives:

  • Educate attendees of ACMG on how to implement gene therapies into their clinic utilizing the expertise of specialists with experience.
  • Provide a mechanism for ACMG attendees to learn best practices from experts in other medical specialties.
  • Empower medical geneticists and support informed clinical decision-making around AAV gene therapies.

Faculty: 
Dr. Aaron Nagiel, Children's Hospital Los Angeles
Dr. Julie Parsons, Children's Hospital Colorado
Dr. Steven Pipe, C.S. Mott Children's Hospital, University of Michigan
Moderator: Dr. Laura Konczal, Case Western Reserve University

Non-accredited

For more information and to register

Amicus Therapeutics

Tuesday, March 12, 2024: 6:15 PM - 7:45 PM
Delta Hotel Toronto - Kensington Ballroom

Optimizing Care for Patients With Fabry Disease: Interactive Case Challenges

A 90-minute engaging symposium comprising interactive patient cases, and time for Q&A and discussion, highlighting the importance of multidisciplinary care in clinical practice and addressing practical issues regarding management of patients with FD. The audience will be encouraged to test their knowledge by participating in challenging scenarios for clinical decision-making.

Learning Objectives:

  • Identify early signs of the multisystemic manifestations of FD and apply guideline-recommended criteria and testing algorithms, including screening of at-risk relatives.
  • Evaluate available clinical data on FD-specific DMTs to support evidence-based treatment decisions.
  • Develop and implement multidisciplinary care plans to manage potential disease complications, using organ-specific biomarkers and QoL measures, for disease monitoring.

Faculty: 
Anjay Rastogi, MD, PhD; UCLA David Geffen School of Medicine, Los Angeles
John L. Jefferies, MD, MPH; School of Public Health, University of Memphis and St Jude’s Children’s Research Hospital, Memphis
Dawn A. Laney, MS, CGC; Emory University School of Medicine

Accredited

For more information and to register

Recordati Rare Diseases

Wednesday, March 13, 2024: 8:00 AM – 9:30 AM
Metro Toronto Convention Center – Room 716 AB

Metabolic Diseases: Strategies to Improve Management of Porphyrias and Porphyria-like Attacks

Patients with acute porphyrias, characterized by an enzymatic defect in the heme biosynthetic pathway, often present with debilitating, life-threatening attacks. Patients with some IEMs present with porphyria-like attacks. When correctly diagnosed, treatment may vary among clinicians who manage these patients. Our faculty will discuss recommended strategies to personalize patient treatment.

Learning Objectives:

  • Discuss disease pathophysiology of clinical manifestations of acute hepatic porphyria to distinguish from other porphyria-like diseases such as hereditary tyrosinemia type
  • Review patient cases whose symptoms include abdominal, neuro, and other acute attacks
  • Implement long-term strategies to manage and minimize disease burden in patients with acute hepatic porphyria.

Faculty

Amy Dickey, MD, MSC; Porphyria Center; Harvard Medical School; Massachusetts General Hospital; Boston, MA
Angelika Erwin, MD, PhD; Cleveland Clinic; Cleveland, OH

Accredited

For more information and to register. RSVP is preferred but walk-ins are welcome based on room capacity.

Sarepta Therapeutics

Wednesday, March 13, 2024: 8:00 AM – 9:30 AM
Metro Toronto Convention Center – Room 714 AB

Looking Through a New Lens: The Invaluable Contributions of Genetic Experts in Neuromuscular Diseases

Join Sarepta Therapeutics for a presentation on the gene targeting modalities in neuromuscular diseases, highlighting heterogeneity in genetic testing & reporting, and the impact of these diagnostic and therapeutic innovations on genetic counselors and clinical geneticists.

Learning Objectives:

  • Review gene targeting modalities in neuromuscular diseases
  • Discuss heterogeneity in genetic testing and reporting
  • Explore the impact of diagnostic and therapeutic innovation on genetic counselors and clinical geneticists

Faculty: 
Joseph Ray, MD; University of Texas Medical Branch
Brianna Gross, MS, CGC; Children's Hospital of Philadelphia

Non-accredited

For more information and to register

Amicus Therapeutics

Wednesday, March 13, 2024: 8:00 AM – 9:30 AM
Metro Toronto Convention Center – Room 701 A

A New Treatment Approach for Late-Onset Pompe Disease

Learning Objectives:

  • Overview of late-onset Pompe disease
  • Review of a new treatment option for patients with late-onset Pompe disease 
  • Understand the perspective of a real patient living with late-onset Pompe disease

Faculty: 
Priya S. Kishnani, MD, MBBS, Duke University Medical Center, Durham, NC 
Maddie, an adult living with Late-Onset Pompe Disease

Breakfast will be available from 7:15 AM
Non-accredited

For more information and to register

The discussion is intended for US healthcare professionals. The treatment being discussed is not authorized for sale in Canada. 

Rhythm Pharmaceuticals Inc.

Wednesday, March 13, 2024: 8:00 am – 9:30 am
Metro Toronto Convention Center – Room 701B

Genetic Testing for Rare Diseases of Obesity

This Genetic Obesity Learning Development (GOLD) Academy program will allow participants to differentiate rare MC4R pathway diseases of obesity from general obesity. Geneticists and genetic counselors will learn key clinical characteristics of rare MC4R pathway diseases of obesity for diagnosis and to identify patients suitable for genetic testing.

Learning Objectives:

  • Introduce rare melanocortin-4 receptor (MC4R) pathway diseases
  • Illustrate how rare variants in key MC4R pathway genes impact body weight
  • Discuss diagnosis of melanocortin-4 receptor (MC4R) pathway diseases associated with obesity
  • Discuss the role of genetic testing in rare genetic diseases of obesity

Faculty:
Vidhu Thaker, MD, Columbia University, Irving Medical Center

Non-accredited

View more information

Register here

Acadia Pharmaceuticals Inc.

Tuesday, March 12, 2024, 6:15 pm – 7:45 pm 
Delta Toronto Hotel; Soco Ballroom

Strategies for Improving Care in Rett Syndrome: Approaches to Genetic Testing and Novel Therapeutics

Getting to know Rett Syndrome, genetic testing, therapeutic considerations. Learners will be better able to diagnose and treat Rett Syndrome/

Learning Objectives:

  •  Increased knowledge regarding genetic mutations with Rett syndrome.
  • Increased knowledge regarding clinical data for therapies studied for the management of Rett syndrome.
  • Greater competence related to interpretation of genetic testing for Rett syndrome.

Faculty:
Jeffrey Neul, MD, PhD, Vanderbilt University Medical Center
Eric Marsh, MD, PhD, Children's Hospital of Philadelphia; University of Pennsylvania Perelman School of Medicine
Jennifer Martelle Tu, MD, PhD, Katie's Clinic for Rett Syndrome, UCSF Benioff Children's Hospitals (Oakland)
Alan K. Percy, MD, University of Alabama at Birmingham
Constance L. Smith-Hicks, MD, PhD, Johns Hopkins University School of Medicine; Kennedy Krieger Institute
Shannon Standridge, DO, MPH, University of Cincinnati College of Medicine, Cincinnati Children’s Hospital Medical Center

Accredited

For more information and to register


 

Sponsors